Publications by authors named "Maria Garcia Agra"
JTO Clin Res Rep
October 2021
Article Synopsis
- PARP inhibition with olaparib was tested in a phase 2 trial on patients with refractory mesothelioma to see if it could improve treatment outcomes through synthetic lethality.
- The study involved 23 patients who received olaparib, showing only one partial response, with most experiencing stable disease, and the median progression-free survival (PFS) was 3.6 months while overall survival (OS) was 8.7 months.
- Results indicated that patients with germline mutations had poorer outcomes compared to wild-type patients, but olaparib was deemed safe with no significant safety issues reported.
